Business UpdateMay 20, 2026, 04:07 PM
Longeveron Secures $15M Investment; HLHS Data Expected Q3 2026
AI Summary
Longeveron Inc. announced a strategic repositioning towards a capital-efficient model focused on securing licensing partnerships for its stem cell therapy, laromestrocel. The company successfully attracted new investment capital and completed a financing transaction in March 2026 for up to $30 million, with $15 million received upfront. Key upcoming milestones include top-line data from the Phase 2b HLHS trial in August 2026, which is eligible for a Priority Review Voucher, and the planned initiation of a Phase 2 PDCM trial in 2027.
Key Highlights
- Strategic repositioning to a capital-efficient model focused on licensing partnerships.
- Secured new investment capital from Coastlands Capital, Janus Henderson, Logos, and Kalehua.
- Completed a financing transaction in March 2026 for up to $30M in gross proceeds.
- Received $15M upfront from the March 2026 financing.
- Top-line 12-month data from Phase 2b HLHS trial (ELPIS II) expected in August 2026.
- HLHS program eligible for a Priority Review Voucher (PRV) valued at $150M-$200M.
- Agreed to sell 50% of potential PRV proceeds to investors from the March 2026 financing.
- FDA accepted IND for Pediatric Dilated Cardiomyopathy (PDCM), Phase 2 trial in 2027.
- Laromestrocel protected by 52 issued patents worldwide.
Price Impact
More from LGVN